이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ibnsina Pharma 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Mohamed Mohsen Mahgoub

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	3.3yrs
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	6.8yrs

최근 관리 업데이트

Recent updates

CEO

Mohamed Mohsen Mahgoub

3.3yrs

테뉴어

Mr. Mohamed Mohsen Mohamed Mahgoub serves as Vice Chairman and Chief Executive Officer at Ibn Sina Pharma (S.A.E) since April 2021. He served as Executive Chairman until April 2021 and has been Director at...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mohamed Mohsen Mahgoub	Vice Chairman & CEO	6.8yrs	데이터 없음	데이터 없음
Mahmoud Abdel-Gawad	Co-CEO & Director	6.8yrs	데이터 없음	4.81% EGP 147.0m
Omar Abdel-Gawad	Co-CEO & Director	6.8yrs	데이터 없음	5.56% EGP 169.8m
Mohamed Mohsen Mahgoub	Director	6.8yrs	데이터 없음	8.12% EGP 247.9m
Hany Hassanein Bader	Director	6.8yrs	데이터 없음	데이터 없음
Abdel Fahmy	Director	6.8yrs	데이터 없음	데이터 없음
Mohamed Abbas Mohamed Zaki	Director	6.8yrs	데이터 없음	2.94% EGP 89.7m
Abdel Aziz Abdel Aziz	Non-Executive Chairman	6.8yrs	데이터 없음	0.15% EGP 4.6m
Ahmed Abdelgawad Mahmoud	Director	no data	데이터 없음	4.61% EGP 140.8m
Ahmed Al Nawawi	Director	no data	데이터 없음	데이터 없음

6.8yrs

평균 재임 기간

경험이 풍부한 이사회: ISPH 의 이사회는 경험(평균 재직 기간 6.7 년)으로 간주됩니다.

Ibnsina Pharma 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

No independent directors

No independent directors

Recent updates

First quarter 2024 earnings released: EPS: ج.م0.08 (vs ج.م0.056 in 1Q 2023)

Investor sentiment deteriorates as stock falls 16%

Investor sentiment deteriorates as stock falls 15%

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improves as stock rises 18%

Price target increased by 16% to ج.م3.43

Investor sentiment improves as stock rises 18%

Investor sentiment improves as stock rises 17%

Consensus EPS estimates increase by 200%

Now 20% undervalued after recent price drop

Now 20% undervalued after recent price drop

Second quarter 2023 earnings released: EPS: ج.م0.001 (vs ج.م0.016 in 2Q 2022)

Investor sentiment deteriorates as stock falls 19%

Investor sentiment improves as stock rises 20%

Price target decreased by 38% to ج.م2.36

Consensus EPS estimates fall by 50%

First quarter 2023 earnings released: EPS: ج.م0.07 (vs ج.م0.04 in 1Q 2022)

Now 20% undervalued after recent price drop

Investor sentiment improves as stock rises 17%

Investor sentiment deteriorates as stock falls 19%

Full year 2022 earnings released: EPS: ج.م0.13 (vs ج.م0.22 in FY 2021)

Price target decreased by 17% to ج.م3.45

Now 21% undervalued

Now 21% undervalued

Price target decreased to ج.م4.00

Price target decreased to ج.م3.45

No independent directors

Price target decreased to ج.م3.82

Investor sentiment improved over the past week

Now 23% undervalued after recent price drop

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Price target decreased to ج.م5.65

Ibn Sina Pharma Company (S.A.E) (CASE:ISPH) acquired El Shorouk Hospital for EGP 430 million.

No independent directors

Full year 2021 earnings: EPS misses analyst expectations

Price target decreased to ج.م6.00

Price target decreased to ج.م6.19

Second quarter 2021 earnings released

Price target decreased to ج.م7.32

First quarter 2021 earnings released: EPS ج.م0.04 (vs ج.م0.043 in 1Q 2020)

New 90-day low: ج.م4.86

Full year 2020 earnings released: EPS ج.م0.19 (vs ج.م0.28 in FY 2019)

Revenue and earnings miss expectations

New 90-day low: ج.م5.09

New 90-day low: ج.م5.18

Price target lowered to ج.م8.04

New 90-day low: ج.م5.77

Price target lowered to ج.م9.00

Ibn Sina Pharma (S.A.E) (CASE:ISPH) signed an agreement to acquire 75% stake in 3elagi Tech.

New 90-day low: ج.م5.93

New 90-day low: ج.م7.27

New 90-day low - ج.م7.63

Earnings released

Price target lowered to ج.م11.62

New 90-day low - ج.م7.73

CEO

테뉴어

이사회 구성원

평균 재임 기간